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Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by
hymenialdisine, a marine sponge constituent
L Meijer1, A-MWH Thunnissen2*, AW White3, M Garnier1, M Nikolic4†,
L-H Tsai4, J Walter5, KE Cleverley6, PC Salinas6, Y-Z Wu7, J Biernat7,
E-M Mandelkow7, S-H Kim2 and GR Pettit3
Background: Over 2000 protein kinases regulate cellular functions. Screening for
inhibitors of some of these kinases has already yielded some potent and selective
compounds with promising potential for the treatment of human diseases.
Results: The marine sponge constituent hymenialdisine is a potent inhibitor of
cyclin-dependent kinases, glycogen synthase kinase-3β and casein kinase 1.
Hymenialdisine competes with ATP for binding to these kinases. A
CDK2–hymenialdisine complex crystal structure shows that three hydrogen
bonds link hymenialdisine to the Glu81 and Leu83 residues of CDK2, as
observed with other inhibitors. Hymenialdisine inhibits CDK5/p35 in vivo as
demonstrated by the lack of phosphorylation/down-regulation of Pak1 kinase in
E18 rat cortical neurons, and also inhibits GSK-3 in vivo as shown by the
inhibition of MAP-1B phosphorylation. Hymenialdisine also blocks the in vivo
phosphorylation of the microtubule-binding protein tau at sites that are
hyperphosphorylated by GSK-3 and CDK5/p35 in Alzheimer’s disease
(cross-reacting with Alzheimer’s-specific AT100 antibodies). 
Conclusions: The natural product hymenialdisine is a new kinase inhibitor with
promising potential applications for treating neurodegenerative disorders. 
Introduction
Alzheimer’s disease (AD) affects 5–10% of the population
over 65 years of age. The dementia associated with AD
results from the selective death of neurons, which is associ-
ated with several anatomo-pathological hallmarks such as
senile neuritic plaques and neurofibrillary tangles. Three
molecular actors clearly play a role in the development of
AD: the amyloid β peptide (Aβ), presenilins-1 and -2 and
the microtubule-associated protein tau. The senile neuritic
plaques form an extracellular core of deposited amyloid β
peptide, derived from proteolytic cleavage of the amyloid
precursor protein (β-APP; reviewed in [1]). The neurofib-
rillary tangles are intracellular aggregates of paired helical
filaments (PHFs) that consist mainly of hyperphosphory-
lated tau proteins. Hyperphosphorylation occurs on more
than 20 sites and is  carried out by two proline-directed
kinases, glycogen synthase kinase-3β (GSK-3β) and cyclin-
dependent kinase 5 (CDK5/p35) (reviewed in [2,3]), and
possibly also by casein kinase 1 (CK1) [4]. Finally, muta-
tions in the transmembrane proteins presenilin genes are
the most common cause of early onset familial AD
(reviewed in [1,5]).
The links between the three proteins, Aβ, presenilins and
tau, have remained elusive until recently (reviewed in
[5,6]). Presenilins appear to be unusual aspartyl proteases
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that activate themselves autocatalytically. They cleave
β-APP to generate Aβ [7], particularly the most aggrega-
tion-prone and neurotoxic amyloid β peptide, Aβ42. Prese-
nilins also directly associate with β-catenin [8,9] and
GSK-3β [10], two components of the Wnt signalling
pathway. Activation of this pathway leads to inhibition of
GSK-3β and results in β-catenin stabilisation. The level of
β-catenin is indeed lower in extracts of brain with prese-
nilin-1 mutations compared with controls or sporadic
Alzheimer’s cases [9]. Interestingly, expressed tau is phos-
phorylated in cells co-transfected with mutant presenilin-1
but not in cells expressing wild-type presenilin-1 [10]. Aβ
treatment of cultured hippocampal neurons results in stim-
ulation of GSK-3β activity [11]. All these results place tau
hyperphosphorylation downstream of presenilins and Aβ
action. Finally, the recent discovery of tau mutations in
AD-related diseases (reviewed in [3]) and the recently
described functions of tau in regulating intracellular traffic
along microtubules [12] have renewed the interest in
understanding the causal link between tau hyperphospho-
rylation and the pathways leading to the cellular modifica-
tions responsible for AD. 
Because protein kinases play an essential role in virtually
all cellular processes and in most diseases, extensive
searches for selective inhibitors of these enzymes have
been carried out (reviewed in [13]). Our laboratory has
focused its efforts on the cyclin-dependent kinase (CDK)
family. CDKs are involved in cell-cycle control (CDK1–4,
6 and 7), thymocyte apoptosis (CDK2), neuronal func-
tions (CDK5) and transcriptional control (CDK7–9)
(reviewed in [14–16]). In nervous tissues CDK5/p35 phos-
phorylates the microtubule-associated proteins tau and
MAP-1B (reviewed in [2,17]), Pak1 kinase [18] and neuro-
filament subunits [19]. Intensive screening has identified
a series of chemical CDK inhibitors (reviewed in [20–22]),
such as olomoucine [23], roscovitine [24,25], purvalanol
[26], flavopiridol [27], indirubins [28] and paullones
[29,30]. Some of these compounds display remarkable
selectivity and efficiency.
In this article we report the discovery of hymenialdisine
(HD, 1; Figure 1) as a very potent inhibitor of CDK1,
CDK2 and CDK5, GSK-3β and CK1. HD has been iso-
lated from several species of marine sponges along with a
variety of related metabolites (Figure 1) [31]. We also
report the crystal structure of a CDK2–HD complex, which
provides an important advance in understanding the mole-
cular mechanism of CDK inhibition. HD was found to
inhibit the in vivo phosphorylation of specific neuronal pro-
teins by GSK-3β and CDK5. In particular, the AD-charac-
teristic phosphorylation of tau is completely inhibited by
HD in vivo. As a potent and rather selective inhibitor of
kinases involved in AD and other degenerative disorders,
HD could be a lead compound for evaluating the impor-
tance of tau hyperphosphorylation in neurodegenerative
diseases and for interfering with this molecular event.
Results
HD potently inhibits CDK1, CDK2, CDK5, GSK-3β and CK1
While screening compounds isolated from marine inver-
tebrates and plants for new CDK inhibitors [32], we dis-
covered HD (1) to be a potent inhibitor of CDK1/cyclin
B (Figure 2, Table 1). HD belongs to a family of chemi-
cally and metabolically related, marine-sponge-derived
natural products (which contain both bromopyrrole and
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Figure 1
Structure of hymenialdisine and related
metabolites isolated from marine sponges. 
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guanidine groups) [31,33–37]. In the presence of 15 µM
ATP, HD was found to inhibit CDK1/cyclin B, CDK2/
cyclin A, CDK2/cyclin E, CDK3/cyclin E and CDK5/p35
with IC50 values of 22, 70, 40, 100 and 28 nM, respec-
tively (Table 1). As observed with olomoucine [23],
roscovitine [24], indirubin-3′-monoxime [28], ken-
paullone [29] and, in contrast to flavopiridol [38], HD had
limited effect on CDK4/cyclin D1 and CDK6/cyclin D2
(IC50 values of 600 and 700 nM, respectively).
HD was next tested on a variety of highly purified kinases
(IC50 values are shown in Table 1). Kinase activities were
assayed with appropriate substrates and 15 µM ATP (this
concentration was comparable to previously published
studies) and in the presence of increasing concentrations
of HD. Most kinases tested were poorly or not inhibited
(IC50 > 1 µM). However, two kinases, GSK-3β and CK1,
were strongly sensitive to HD (IC50 values of 10 and
35 nM, respectively; Figure 2, Table 1). The HD-sensi-
tive kinases were also assayed in vitro with physiologically
relevant substrates: a fragment of presenilin-2 [39] for
CK1 (Figure 3), Pak1 [18] for CDK5/p35 (Figure 4), the
insulin-receptor substrate IRS-1 [40] (data not shown) or
tau for GSK-3β (Figure 5). The sensitivity of the kinases
towards HD was comparable to the sensitivity of the same
kinases assayed with more artificial substrates.
We next tested some natural HD-related compounds iso-
lated from marine sponges and some synthetically modified
HD analogues on CDK1/cyclin B, CDK5/p35, GSK-3β and
CK1 (Figure 2; Table 2). HD was the most active com-
pound. Interestingly, dibromocantharelline (10) displayed a
significant inhibitory effect towards GSK-3β (IC50 =3 µM).
Hymenidin (13) was selective for CDK5. 
HD is a competitive inhibitor of ATP
To investigate the mechanism of HD action, kinetic experi-
ments were performed by varying both ATP levels and HD
concentrations (Figure 6a). Double-reciprocal plotting of
the data demonstrates that HD is a competitive inhibitor for
ATP. The apparent inhibition constant (Ki) was 50 nM.
HD does not act by displacing cyclin B from CDK1
(Figure 6b).
Crystal structure of the CDK2–HD complex
Crystal structures of CDK2 complexed with several
inhibitors have been reported: isopentenyladenine [41],
olomoucine [41], des-chloro-flavopiridol [42], roscovitine
[25], staurosporine [43], purvalanol [26] and indirubin-
3′-monoxime [28]. All these compounds bind in the ATP-
binding pocket located in the groove between the small
and the large lobes of CDK2. To study in detail the
essential binding interactions of HD, and to compare
Research Paper  Protein kinase inhibition by hymenialdisine Meijer et al. 53
Figure 2
Inhibition of CDK1/cyclin B by HD analogues. CDK1/cyclin B was
assayed as described in the Supplementary material section. Activity is
presented as % of maximal activity (i.e. in the absence of inhibitors). 
Table 1
Kinase inhibition selectivity of hymenialdisine.
Enzyme IC50 (nM)
CDK1/cyclin B 22
CDK2/cyclin A 70
CDK2/cyclin E 40
CDK3/cyclin E 100
CDK4/cyclin D1 600
CDK5/p25 28
CDK6/cyclin D2 700
Erk1 470
Erk2 2000
c-raf > 10,000
MAPKK 1200
c-Jun amino-terminal kinase 8500
Protein kinase C α 700
Protein kinase C β1 1200
Protein kinase C β2 1700
Protein kinase C γ 500
Protein kinase C δ 1100
Protein kinase C ε 6500
Protein kinase C η 2000
Protein kinase C ζ 60,000
cAMP-dependent protein kinase 8000
cGMP-dependent protein kinase 1700
GSK3-β 10
ASK-γ (plant GSK-3) 80
Eg2 kinase 4000
CK1 35
CK2 7000
Insulin receptor tyrosine kinase 75,000
c-src tyrosine kinase 7000
c-abl tyrosine kinase 4000
Topoisomerase I –(10,000)
Topoisomerase II α –(10,000)
Enzyme activities were assayed as described in the Supplementary
materials section, in the presence of increasing HD concentrations.
IC50 values were calculated from the dose-response curves. –, no
effect at the highest dose tested (in parentheses).
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these with the interactions observed in the other
CDK2–inhibitor complexes, we determined the structure
of a CDK2–HD complex at 2.1 Å resolution (Table S1 in
the Supplementary material section). Treatment with a
cross-linking agent, prior to soaking, was necessary to
prevent the crystal from cracking. The final model con-
sists of 274 amino acid residues, one bound HD molecule,
85 solvent molecules and four molecules of ethylene
glycol, with a crystallographic R-factor of 19.2% (Rfree of
26.7%) and good geometry. Residues 36–44 and 149–163
of CDK2, which are part of two highly flexible loops, were
left out from the final model because of weak or missing
electron density. All nonglycine residues in the CDK2
model have mainchain torsion angles that lie well within
54 Chemistry & Biology 2000, Vol 7 No 1
Figure 3
HD inhibits the phosphorylation of presenilin-2 by CK1 in vitro. A
bacterially expressed fusion protein between presenilin-2 and maltose-
binding protein (PS-2–MBP) was phosphorylated in vitro with CK1 in
the presence of increasing HD concentrations and resolved by sodium
dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–PAGE),
followed by autoradiography.
Figure 4
HD inhibits phosphorylation of Pak1 by CDK5/p35 in vitro and in vivo.
Rat embryo cortical neurons were exposed to various HD
concentrations for 1 h. Pak1 was then immunoprecipitated and its
kinase activity towards histone H4 measured. (a) The level of H4
phosphorylation following SDS–PAGE of the substrate is shown.
Numbers correspond to the quantification of the autoradiography.
(b) Western blots show the amounts of Pak1 and p35. Note an
increase in p35 levels as a consequence of CDK5 inhibition.
Table 2
Inhibition of CDK1, CDK5 and GSK-3β and CK1 by HD analogues.
IC50 (nM) 
Compound CDK1/cyclin B CDK5/p25 GSK3-β CK1
1 Hymenialdisine 22 28 10 35
Hymenialdisine–platinum complex 30 200 130 1000
Diacetylhymenialdisine 130 1500 160 550
Diacetyldebromohymenialdisine 1300 3000 600 1100
4 Stevensine/odiline 70,000 – (100,000) – (100,000) – (100,000)
5 Axinohydantoin 4000 7000 3000 4500
8 Dibromophakellstatin – (10,000) – (100,000) > 10,000 – (10,000)
9 Agelastatin A – (100,000) – (100,000) 12,000 – (100,000)
10 Dibromocantharelline > 100,000 > 100,000 3000 – (100,000)
11 Dispacamide A – (100,000) – (100,000) – (100,000) – (100,000)
12 Clathrodin > 100,000 > 100,000 10,000 – (100,000)
13 Hymenidin > 100,000 4000 12,000 > 100,000
14 Oroidin > 100,000 50,000 20,000 > 100,000
15 Agelongine – (100,000) – (100,000) – (100,000) – (100,000)
6 Dibromoageliferin > 100,000 > 100,000 11,000 – (100,000)
7 Sceptrin – (100,000) – (100,000) – (100,000) – (100,000)
Numbers refer to structures shown in Figure 1. Enzyme activities were
assayed as described in the Supplementary material section, in the
presence of increasing HD concentrations. IC50 values were
calculated from the dose-response curves. –, no effect at the highest
dose tested (in parentheses).
cm7109.qxd  02/08/2000  02:02  Page 54
the energetically favorable regions of the Ramachandran
plot [44], except for two residues, Glu73 and Arg126, that
have backbone conformations falling just outside the
‘additional allowed’ region in φ–ψ space.
HD was unambiguously localised in a Fourier difference
map, confirming that this inhibitor also binds in the ATP-
binding pocket (Figure 7a). A representation of the
binding-site interactions is shown in Figures 7b and 8.
The pyrroloazepine double-ring system of HD fills a
shallow hydrophobic pocket formed by Ile10, Val18,
Ala31, Val64, Phe80 and Leu134, making several van der
Waals contacts with the sidechain atoms of these residues.
In addition, three hydrogen bonds are formed with the
backbone of CDK2, between the N1 atom of the pyrrole
ring and the carbonyl oxygen of Leu83, between the O1
carbonyl oxygen of azepine ring and the backbone amide
of Leu83, and between the N2 amide of the azepine ring
and the carbonyl oxygen of Glu81. The bromine atom
bound to the pyrrolo ring of HD points towards the
outside of the ATP-binding pocket, where it is partly
exposed to solvent, but also packed against the mainchain
carbonyl oxygen atoms of Ile10 and His84, and the
sidechains of Ile10 and Leu134. Binding of the guanidine
ring system of HD involves a few van der Waals contacts,
mainly with the sidechain of Val18, in addition to one
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Figure 5
HD inhibits tau phosphorylation by GSK-3β in vitro and in vivo.
(a) Bacterially expressed recombinant human tau was phosphorylated
in vitro with GSK-3β in the presence of increasing HD concentrations
and resolved by SDS–PAGE, followed by autoradiography. (b) Sf9
cells expressing htau23 were left untreated (–), or exposed to okadaic
acid (OA), HD or flavopiridol (FL) for 5 h. Cell lysates (3 µg htau23)
were resolved by SDS–PAGE, stained with Coomassie blue or
immunoblotted with various antibodies: K9JA (a pan-tau antibody)
recognizes all preparations that contain tau; AT8, AT180 and PHF1
are specific for different phosphorylated SP or TP motifs; AT100
recognizes tau phosphorylated at Thr212 and Ser214, a highly
specific reaction for the Alzheimer’s form of tau.
Figure 6
HD acts by competing with ATP. (a) Double reciprocal plots of kinetic
data from assays of CDK1/cyclin B protein kinase activity at different
concentrations of hymenialdisine. Enzyme activities were assayed as
described in the Supplementary material section. (a) 1/V versus 1/ATP
primary plot. ATP concentrations in the reaction mixture varied from
0.05 to 0.25 mM, concentration of histone H1 was kept constant at
0.7 mg/ml. Inset, secondary re-plots of slopes versus concentration
from primary plots. The apparent inhibition constant (Ki) is indicated by
an arrow. (b) HD does not release cyclin B from CDK1. p9CKShs1-
sepharose-immobilised CDK1/cyclin B was exposed to HD for 30 min,
washed and analysed by western blotting with anti-cyclin B and anti-
PSTAIRE antibodies. 
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direct hydrogen bond between the N5 amino group of the
guanidine and one of the sidechain oxygen atoms of
Asp145, and two water-mediated hydrogen bonds
between the O2 of HD and the mainchain NH of Asp145,
and between the N5 of HD and the mainchain carbonyl of
Gln131. Comparison with the apo-CDK2 and CDK2–ATP
structures [45] reveals a large movement of Asp145 upon
binding of HD, consisting of a 1 Å shift of the Cα atom,
and a rotation of the sidechain of ~90° around the Cα–Cβ
bond away from the HD guanidine ring. All the other
residues in contact with the inhibitor have similar confor-
mations to those observed in the apo-CDK2 and
CDK2–ATP structures.
Comparison of CDK2–HD with other complexes
To provide a structural basis for understanding the potency
of HD we compared the structure of the CDK2–HD
complex with those of CDK2 complexed with ATP [45],
staurosporine, flavopiridol and with the purine analogues
olomoucine, roscovitine and purvalanol, as well as with the
structure of the cyclin A–CDK2–ATP complex [46].
The hydrophobic double-ring system of HD binds at
approximately the same position in CDK2 as the purine
ring of ATP in the CDK2–ATP complex, similar to the
positions of the double-ring systems in the other CDK2–
inhibitor complexes (Figure 9). Although the orientation of
the different double-ring systems varies significantly among
the different inhibitors, it is restrained by the necessity to
provide optimal shape complementarity with the shallow
ATP-purine binding pocket while allowing the formation of
a number of hydrogen bonds with the backbone of residues
81–83 at the cross-over connection in CDK2. The hydro-
gen-bonding interactions in the CDK2–HD complex seem
to be the most favorable of all the CDK2–inhibitor com-
plexes studied so far. The hydrogen bonds between N2 and
the peptide oxygen of Glu81, and between O1 and the
peptide amide of Leu83 resemble closely those between
the adenine base of ATP and CDK2 and those in the com-
plexes with staurosporine and flavopiridol. The third hydro-
gen bond in the CDK2–HD complex with the mainchain
carbonyl of Leu83, is absent in these complexes, and can be
observed only in the complexes with the three purine-
based inhibitors olomoucine, roscovitine and purvalanol.
Similar to HD, these latter three inhibitors also form three
hydrogen bonds with the cross-over connection, but their
interaction with the Glu81 peptide oxygen is much weaker,
involving a rare C–H...O hydrogen bond with the acidic C8
atom of the purine ring [26].
The bromine atom of HD is bound close to a region in
CDK2 that in the other CDK2–inhibitor complexes is occu-
pied by a benzyl group. Binding of a hydrophobic group in
this region, where it can pack against the sidechains of
56 Chemistry & Biology 2000, Vol 7 No 1
Figure 7
Overall structure of a CDK2–HD crystal. (a) Stereo view of the
electron density for HD. The electron density at 2.1 Å resolution was
drawn from a Fo–Fc difference omit electron density map calculated
after simulated annealing refinement. The map was contoured at 2.0 σ.
(b) Backbone drawing of CDK2 with HD in the ATP-binding pocket
between the smaller amino-terminal domain and the larger
carboxy-terminal domain. Secondary structural elements are indicated
by arrows for β strands and coils for α helices, and labelled as in the
apo-enzyme [74]. Drawn using MOLSCRIPT [75].
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Ile10, Phe82 and the backbone of residues 82–84, is impor-
tant for increasing the specificity of inhibitors for CDK2
[25,26,41]. Although the bromine in HD cannot provide the
same number of interactions as a benzyl ring, the presence
of this atom in HD probably contributes significantly to its
binding affinity and specificity towards CDK2, as can been
seen from the inhibitory activities of various HD analogues
in Table 2 and Figure 2.
The region of CDK2 occupied by the guanidine ring of
HD is also interesting. A superposition with the other
CDK2–inhibitor complexes shows that only the flavopiri-
dol and staurosporine inhibitors have groups bound in this
region of CDK2, which partly overlaps with the pocket
where the α-phosphate of ATP binds. Comparison of the
structure of the CDK2–HD complex with that of the
CDK2–flavopiridol complex [42] reveals a number of
striking similarities between the binding modes of these
structurally diverse inhibitors. The O2 carbonyl oxygen of
HD is located close to the position of the O7 hydroxyl
group of the flavopiridol, which emanates from the benzo-
pyran ring bound at the purine region of the ATP-binding
pocket. In both inhibitors the oxygen atoms form a water-
mediated hydrogen bond with the mainchain amide of
Asp145. Furthermore, the N5 amino group at the guani-
dine ring of HD is located near to the position of the posi-
tively charged amine group of the piperidinyl ring in the
CDK2–flavopiridol complex. Both atoms are in hydrogen-
bonding distance with the sidechain carboxylate of
Asp145. The energetically favorable interaction between
the positively charged amine group of the flavopiridol and
the negatively charged carboxylate of Asp145 would make
an important contribution to the binding strength of this
inhibitor to CDK2. A similar interaction seems possible in
the CDK2–HD complex, as under physiological condi-
tions the guanidine ring is likely to be at least partly proto-
nated at N3, thus providing a (partly) positive charge
delocalised between N3, C11, N4 and N5 [33]. Also the
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Figure 8
Protein–inhibitor interactions in the
CDK2–HD complex. (a) Stereo diagram
showing the refined structure of HD in the
ATP-binding pocket of CDK2. Inferred
hydrogen bonds are shown as thin dotted
lines. Oxygen atoms are shown in red,
nitrogen atoms in blue and bromine in green.
(b) Schematic illustration of the interactions
between CDK2 and HD. Protein sidechain
contacts are indicated by lines connecting to
the respective residue box, whereas
interactions with mainchain atoms are shown
as lines to the specific mainchain atom. Van
der Waals contacts are indicated by dotted
lines and hydrogen bonds by broken lines. 
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movement of Asp145 is conserved in both CDK2–
inhibitor complexes. It is also seen in the indirubin-5-
sulphonate–CDK2 structure [28]. Asp145 is part of the
conserved Asp–Phe–Gly (DFG) motif found in most
protein kinases [47]. Although significantly different from
those in the CDK2–ATP complex, the position and con-
formation of Asp145 in both CDK2–inhibitor complexes
is, in fact, very similar to those in the functionally more
relevant cyclin A–CDK2–ATP complex [46] (Figure 9a).
In vitro inhibition of presenilin phosphorylation
We next investigated the effects of HD on the in vitro and
in vivo phosphorylation of various protein substrates rele-
vant to AD. The large hydrophilic loop of presenilin-2
between transmembrane domains 6 and 7 is a substrate for
both CK1 and CK2 in vitro; this domain is phosphorylated
in vivo [39]. Using a presenilin-2–maltose-binding protein
(MBP) fusion protein as an in vitro substrate for CK1 we
observed a dose-dependent inhibition of presenilin-2
phosphorylation by HD (Figure 3). MBP alone was not
phosphorylated by CK1 (data not shown). 
In vitro and in vivo inhibition of Pak1 phosphorylation by
neuronal CDK5/p35
Among the physiological substrates of CDK5/p35 is the
neuronal kinase Pak1 [18]. Both Pak1 and p35 associate
with Rac, a small GTPase of the Rho family. Phosphoryla-
tion of Pak1 by CDK5/p35 results in inhibition of the Pak1
kinase activity [18]. Roscovitine inhibits CDK5/p35 and
the resulting down-regulation of Pak1 both in vitro and in
vivo [18]. These experiments were repeated with HD
(Figure 4). First CDK5/p35 was immunoprecipitated from
P02 rat cortices and its kinase activity towards
GST–Pak1K299 (a kinase-dead Pak1 mutant) in the pres-
ence of HD, roscovitine or dimethylsulfoxide (DMSO) was
assayed as described previously [18]. A dose-dependent
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Figure 9
Stereo views comparing the binding of various
CDK2 ligands or inhibitors. (a) Superposition
of HD (black bonds) on ATP (white bonds) in
apo-CDK2 and on ATP (yellow bonds) in the
cyclin A–CDK2 complex. (b) Superposition of
HD on olomoucine (white) and purvalanol
(yellow). (c) Superposition of HD on
flavopiridol. The CDK2 backbone atoms of
residues 81–84, and the sidechain of Asp145
in the CDK2–HD complex are shown in ball-
and-stick representation with black bonds.
The same residues from the superimposed
CDK2–ligand complex are shown as bonds.
In (a) the thin bonds refer to the apo-enzyme,
the thick bonds to the cyclin A–CDK2 dimers.
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inhibition of CDK5 by HD was observed (IC50 values
between 10 and 100 nM; Figure 4a). In vivo experiments
were next performed using cultured neurons from E18 rat
embryo cortices (Figure 4b). As previously shown [48], the
amount of p35 increases with the extent of CDK5/p35
kinase inhibition. An increase in Pak1 activity was
observed, consistent with an inhibition of endogenous
CDK5 activity (Figure 4b).
HD inhibits MAP-1B phosphorylation by GSK-3 in
cerebellar granule cell neurons
GSK-3β is inhibited by both WNT-7a and lithium in cere-
bellar granule cell neurons [49,50]. WNT-7a and lithium
induce axonal remodelling and loss of a phosphorylated
form of MAP-1B, a microtubule-associated protein
involved in axonal outgrowth [50]. As GSK-3β phosphory-
lates MAP-1B at a site recognised by the antibody SMI-31,
inhibition of GSK-3β by WNT or lithium results in the loss
of a phosphorylated MAP-1B, MAP-1B-P [50]. To examine
the effect of HD on neuronal morphology and MAP-1B
phosphorylation cerebellar granule cells were cultured in
different concentrations of HD. In control cells with long
processes and very few filopodia (Figure 10a), MAP-1B-P is
present along the entire length of the axon (Figure 10b). At
low concentrations (1 µM, 10 µM and 25 µM) HD had no
noticeable effect on the morphology of the cells
(Figure 10c), or the distribution of MAP-1B-P (Figure 10d).
However, 50 µM HD treatment induced axonal spreading
and branching and a shortening of axon length
(Figure 10e), with a concomitant loss of MAP-1B-P from
most of the axonal processes (Figure 10f). Treatment of
cultures with 100 µM HD caused a more dramatic change
in cell morphology characterised by extensive branching
and spreading, shortening of axon length and an increased
number of filopodia (Figure 10g), together with loss of
MAP-1B-P from processes (Figure 10h). The axonal
remodelling observed was associated with a loss of stable
microtubules from spread areas of the axons (data not
shown). HD induces the loss of MAP-1B-P in a dose-
dependent manner as determined by western blotting
(Figure 10i). This effect is similar to that observed with
lithium or WNT-7a treatment [50]. As we have shown that
HD inhibits GSK-3β directly, our results suggest that the
loss of MAP-1B-P and axonal remodelling induced by HD
is a consequence of GSK-3β inhibition in cultured neurons.
Inhibition of tau phosphorylation by GSK-3
The microtubule-binding protein tau is the substrate of
several kinases, including GSK-3β and CDK5/p35. Bacteri-
ally expressed recombinant human tau was indeed phos-
phorylated in vitro by GSK-3β and this phosphorylation was
inhibited in a dose-dependent manner by HD, with an IC50
value of ~33 nM (Figure 5a). We next investigated the
effect of HD on the in vivo phosphorylation of human tau23
expressed in Sf9 cells (Figure 5b). Cells were left untreated
(–), or exposed to 0.2 µM okadaic acid (OA), 50 µM HD or
50 µM flavopiridol (FL), a CDK inhibitor that also inhibits
GSK-3β (L.M., unpublished observations). Htau23 was
resolved by using SDS–PAGE followed by immunoblotting
with various antibodies. K9JA (a pan-tau antibody) recog-
nizes all preparations that contain tau. AT8, AT180 and
PHF1 are specific for different phosphorylated Ser–Pro (SP)
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Figure 10
HD induces axonal remodelling and decreases GSK-3-induced
MAP-1B-P levels in axonal processes. (a,b) Double immunofluorescence
staining for GAP-43 (red) and MAP-1B-P (green) shows that MAP-1B-P
is present along the axon. (c) A 20 h treatment with 10 µM HD has no
obvious effect on cell morphology, or (d) MAP-1B-P localisation. Arrows
indicate the same cells. (e) 50 µM HD treatment induces axonal
spreading, shortening of the axon and (f) loss of MAP-1B-P from axonal
processes. Arrows indicate the same cells. (g)100 µM HD treatment
causes a more dramatic change in cell morphology with spreading and
branching along the axon, an increased number of filopodia and
shortening of the axon. (h) MAP-1B-P is lost from most of the axonal
processes. Arrows indicate axons where MAP-1B-P is lost. Bar = 20 µm.
(i) Western blotting analysis of cell lysates shows a gradual decrease in
MAP-1B-P in response to increasing doses of HD.
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or Thr–Pro (TP) motifs: Ser202 and Thr205, Thr231 and
Ser235, and Ser396 and Ser404, respectively, (as numbered
in htau40, the longest human tau isoform). AT100 recog-
nizes tau phosphorylated at Thr212 and Ser214; this reac-
tion is highly specific for the Alzheimer’s form of tau but
occurs in Sf9 cells as well, provided both sites are phospho-
rylated [51]. The disappearance of AT100 signal following
treatment with HD or flavopiridol indicates that both com-
pounds are able to inhibit GSK-3β like activity in Sf9 cells.
Discussion
HD is a new and potent inhibitor of CDKs, GSK-3β and
CK1. We have characterised its molecular interaction with
CDK2, as well as its powerful effects on the in vitro and in
vivo phosphorylation of neuronal proteins. Particularly
interesting is the inhibitory effect of HD on the in vivo
phosphorylation of the AD protein tau. 
HD has been found in species of marine sponges belong-
ing to the Agelasidae, Axinellidae and Halichondriidae fami-
lies [33–36,52]. These animals contain a variety of
substances that are clearly metabolically related to HD
(e.g. Figure 1). The synthetic and degradation pathways of
HD and how the related molecules fit in these pathways
still remain to be investigated. Some experimental evi-
dence suggests that oroidin and 4,5-dibromopyrrol-2-car-
boxylic acid, from Agelas clathrodes, act as ‘feeding
deterrent agents’, protecting the sponge from predation by
several species of fish [53].
Although HD inhibits CDKs by competition with ATP, it
belongs to a new class of chemical CDK inhibitors. Previ-
ously described antagonists all act by competing with ATP
binding. All interact with the ATP-binding pocket
through two or three hydrogen bonds with the Glu81 and
Leu83 residues of CDK2. The ATP-binding pocket of
CDKs (and presumably of other kinases) can therefore
accommodate an unexpectedly large variety of structures,
with high affinity and high selectivity. 
The potency of HD as a CDK inhibitor can be explained
by analysing its binding interactions in the CDK2–HD
crystal structure. Most of these interactions involve atoms
of the HD pyrroloazepine ring system (which contribute
31 of the total 45 van der Waals contacts and three of the
four direct hydrogen bonds). The van der Waals packing
and hydrogen-bonding contacts of the HD double-ring
system with the same, mostly hydrophobic enzyme
residues that form the pocket for the adenine base in the
ATP complex structure is a common feature in all crystal-
lographically determined binding modes of CDK2
inhibitors, emphasising the anchoring nature of these
interactions. Affinity and selectivity of the inhibitors is
further built up from the binding of substituents that
emanate from the double-ring system, which are different
among the different inhibitors. One way to assess the
binding strength of a ligand from its binding mode in a
protein–ligand complex is the shape complementarity of
the contact surfaces of both partners. These values are cal-
culated from the structures of the different CDK2–
inhibitor complexes (Table S2 in the Supplementary
matieral section). For the three structurally related purine-
based inhibitors, there is a good correlation between the
inhibitory strength, and the shape complementarity with
the inhibitor-binding pocket. For the structurally more
diverse inhibitors des-chloro-flavopiridol and HD,
however, shape complementarity alone seems to be a poor
indicator of inhibitor strength. We believe that HD
achieves tight binding to CDK2 through the contribution
of strong specific hydrogen bonds, and a short-range elec-
trostatic interaction between the acidic Asp145 and the
basic guanidinium ring. In addition, a significant entropic
factor could be involved in the binding of HD to CDK2,
as the entropy penalty for the complex formation is
minimal due to the rigid nature of the inhibitor. Neverthe-
less, one can imagine that drug-design studies could sig-
nificantly improve the binding by optimising the shape
complementarity of HD, for instance by replacing the
bromine atom with more bulky groups. Unfortunately, at
this point we are unable to identify the common structural
features of the kinases for which HD is a potent inhibitor,
nor explain why other kinases are not sensitive. Alignment
of human CDK2, CK1 and GSK-3β (data not shown) is
not especially helpful. Only the crystal structure of a
CK1–HD or GSK-3β–HD will provide a clear view of the
key interacting residues underlying the selectivity.
Investigating the selectivity of a compound is not a trivial
matter. We feel that what is really important is the in vivo
selectivity, the range of targets that an inhibitor will actu-
ally interact with within a cell. One method we are cur-
rently developing is the purification of targets using
affinity chromatography on immobilised inhibitors. The
crystal structure of the HD–CDK2 complex provides pre-
cious information with respect to its orientation within the
ATP-binding pocket, showing which part of HD is acces-
sible to solvent. This is where a linker could be attached
to tether the inhibitor to a solid matrix while maintaining
free access to its kinase targets. Using this approach with
purvalanol, based on the CDK2–purvalanol crystal struc-
ture [26], we recently identified the intracellular targets of
purvalanol in a variety of cells and tissues (Knockaert et al.
and L.M., unpublished observations).
We are presently re-isolating HD-related compounds from
marine sponges to investigate their CDK, GSK-3β and
CK1 inhibitory properties. HD, the most abundant
metabolite (up to 0.5% of the sponge dry weight), can also
be used as a starting point for various chemical modifica-
tions, leading to new derivatives and this research is in
progress in our laboratories. Furthermore, HD has been
synthesised [54–56] and we are working on generating
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new synthetic analogues. Finally, we have initiated a com-
binatorial chemistry approach to generate an even larger
number of HD-related molecules. These various
approaches, also partially guided by the CDK2–HD struc-
ture, should complement the initial structure–activity
study presented in this paper. Through these various
approaches, we hope to generate more selective and more
cell-permeable HD analogues.
The kinases responsible for the hyperphosphorylation of
tau and MAP-1B observed in AD certainly constitute rea-
sonable screening targets. By acting on GSK-3β, CDK5
and CK1, the major kinases involved in this process, HD
is a strong lead compound from which clinically useful
drugs could potentially be generated. In addition to AD,
HD could be used to target other neuronal disorders. For
example, CDK5 is present in Lewy bodies, the typical
inclusions observed in neurons in Parkinson’s disease [57]
and in glial cytoplasmic inclusions that characteristically
occur in the oligodendrocytes of patients with multiple
system atrophy [58]. CDK5 also accumulates in axonal
swellings in dogs with hereditary canine spinal muscular
atrophy [59]. Lithium is widely used for treatment of
mood disorders, but its exact mechanism of action is not
clearly defined. It appears to inhibit GSK-3β in a non-
competitive way [60], thereby reducing tau phosphoryla-
tion [61–63]. The efficiency of HD towards GSK-3β
(IC50 = 35 nM) compares very favourably with the relative
efficacy of lithium towards GSK-3β (IC50 = mM). 
Insulin acts by activating a protein kinase cascade leading
to the inhibition of GSK-3β. This results in the stimula-
tion of glycogen synthase and protein synthesis (reviewed
in [64]). As a consequence, any GSK-3β inhibitor is a
potential insulino-mimetic and could be useful in treating
diabetes. This is certainly worth exploring with HD and
its analogues.
Finally, it has been reported that HD inhibits NFκB
activity through an alternate mechanism to inhibiting
protein kinase C or IκB phosphorylation [65,66]. HD has
also been reported to have anti-inflammatory properties
[67]. The possibility that CDKs, GSK-3β, CK1, or
another unknown kinase target of HD, are involved in
NFκB activation and in adjuvant-induced arthritis
deserves further investigation. 
Significance 
Among the estimated 2000 human protein kinases,
cyclin-dependent kinase 5 (CDK5) and glycogen syn-
thase kinase 3 (GSK3) appear to play an essential role in
the hyperphosphorylation of substrates involved in
Alzheimer’s disease. While screening through a large
collection of natural products derived from marine
organisms, we identified hymenialdisine (HD) as a
potent and rather selective inhibitor of these protein
kinases. HD acts by competing with ATP for binding at
the catalytic site of the kinase. HD was co-crystallised
with CDK2, and the resolution of this complex structure
provides data on the orientation and interactions of the
inhibitor in the ATP-binding pocket of the kinase. It also
allows some speculations on the further optimisation of
HD analogues as kinase inhibitors. The in vivo effects of
HD on kinases was demonstrated in several models.
These results should encourage the study of HD as a
lead compound in the treatment of neurodegenerative
disorders. 
Materials and methods
Preparation of CDK2–HD crystals
Human CDK2 was purified and crystallized as previously described
[68]. Initial attempts to obtain CDK2–HD crystals, by adding small
amounts of solid inhibitor to the crystal-containing drops, were unsuc-
cessful because of insolubility of the inhibitor. When soaking with HD
solubilized in the presence of 1% DMSO, however, it was observed
that crystals cracked and dissolved at inhibitor concentrations as low
as 10 µM, strongly suggesting that binding occurred (the same
DMSO-containing solution without inhibitor did not harm the crystals).
A procedure involving chemical cross-linking was employed to prevent
crystals from cracking. Crystals were first soaked in a solution contain-
ing 0.5 mM ATP, 1 mM MgCl2 for 2 h, then cross-linked with 0.1% glu-
taraldehyde, for 1 h at 4°C. After extensive washing the crystals were
transferred to an inhibitor solution in 0.2 M HEPES, 5% ethylene glycol
and 1% DMSO. This protocol allowed crystals to be soaked at
inhibitor concentrations up to 0.5 mM, for several days, without
showing any damage.
Determination of the CDK2–HD crystal structure
X-ray diffraction data to 2.1 Å resolution were collected on a single
CDK2–HD crystal using an R-Axis II image plate detection system,
mounted on a Rigaku rotation-anode generator. Data were collected at
120 K to prevent radiation damage of the crystal. Just prior to freezing,
the crystal was transferred to a cryo-protecting solution containing
25% ethylene glycol. Flash freezing was achieved in a dry nitrogen
stream using a Molecular Structure Corporation cryodevice. Freezing
altered slightly the unit cell dimensions and increased the mosaic
spread from 0.2–0.6°. The cross-linking by itself did not alter the dif-
fraction characteristics significantly. The intensity data were processed
with the DENZO and SCALEPACK programs [69]. The program
TRUNCATE, as implemented in the CCP4 suite [70], was used to
obtain the final set of structure factor amplitudes. A summary of the
data processing statistics is presented in Table S1 in the Supplemen-
tary material section. Refinement of the CDK2–HD complex was
started from the coordinates of the highly refined CDK2–ATP model.
All refinement steps were carried out using the program X-PLOR [71].
Molecular replacement followed by rigid body refinement was neces-
sary to successfully reorient and reposition the CDK2 molecule in the
unit cell of the frozen crystal. The model was then further refined using
several rounds of conjugated-gradient energy minimization. After this
stage clear electron density, calculated from 2Fo–Fc and Fo–Fc Fourier
maps, indicated the binding mode of the hymenialdisine inhibitor. Initial
coordinates and geometric restraint terms for hymenialdisine were
taken from the small molecule structure of Mattia et al. [72]. Refine-
ment of the CDK2–HD model was then pursued with several rounds of
both X-ray restrained energy minimization and molecular dynamics,
alternated with model building. Towards the end of the refinement
several water molecules and a few molecules of ethylene glycol were
added to the model. The stereochemistry of the CDK2–HD model was
verified using the software package PROCHECK [73]. 
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Accession numbers
The co-ordinates of the CDK2–hymenialdisine structure have been
depostied in the PDB  under the code 1DM2.
Supplementary material
Supplementary material including details of diffraction data collection and
refinement statistics of the CDK2–HD complex, buried areas of CDK2
and ligands, chemicals and reagents used, buffers, kinase preparations
and assays, electrophoresis and blotting, in vitro and in vivo phosphoryla-
tion of presenilin-2, Pak1, MAP-1B and tau and MAP-1B immunochem-
istry is available at http://current-biology.com/supmat/supmatin.htm.
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